← Back to Calendar

Cytokinetics Q4 2025 Earnings

Cytokinetics · $CYTK
Standard Review Earnings
Catalyst Date
February 27, 2026
Date Status
45d ago (past)
Review Type
Standard (10 mo)

Live Company Data NMS

Updated 1m ago · Data: FMP
Current Price
$65.01 +71.76%
+$27.16 today
Day: $63.95 – $65.50
Market Cap
N/A
Shares out: 123.16M
Float: 122.30M
52-Week Range
$29.31
$70.98
Current price is at 86% of 52-week range
Avg Volume
1.87M
Beta
0.48
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $CYTK catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q4 2025 earnings + MYQORZO commercial launch update

Key Notes

Q4 2025 earnings reported February 27, 2026. Q4 revenue $17.8M (FY2025 $88.0M including $52.4M Bayer tech transfer). Net loss Q4 $183M (-$1.50/sh). Year-end cash ~$1.22B. MYQORZO FDA approved Dec 19 2025; launched Jan 2026. Key updates: ACACIA-HCM (non-obstructive) readout expected Q2 2026; MAPLE-HCM sNDA review expected by Q4 2026.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar